JD Bioscience Inc. (JDB) products

NASH, an advanced form of non-alcoholic fatty liver disease (NAFLD), can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Genetic factors, environmental factors, and microbiome alterations are mainly involved in disease progression. Experts estimated that 24% of U.S. adults have NAFLD and more than 6.5% of them have NASH (NIH report, 2021). 20~30% of patients with NASH progress to liver fibrosis in 7 years, and 20% of them progress to cirrhosis in two years. However, since no drugs for NASH are commercially available, off-label drug use is the only available treatment option.

IBD, including ulcerative colitis (UC) and crohn’s disease (CD) can be caused by genetic and environmental factors and can induces uncontrolled activation of intestinal immune cells. Pro-inflammatory cytokines, such as IL-6 and TNF, produced by activated immune cells are suggested to drive the perpetuation of inflammation and tissue damage.

JDB is developing a novel drug candidate for heart disease that can rescue heart function at a cellular level, and can eventually help improving heart function.

JDB is developing a novel drug candidate for acute pancreatitis that can effectively reduce inflammation of the pancreas by modulating mitochondrial functions in pancreatic cells.